Multiple myeloma (MM) and its precursor monoclonal gammopathy of undetermined
significance (MGUS) are distinct disorders that likely originate in the setting of chronic …

Polyamines are ubiquitous, amine-rich molecules with diverse processes in biology. Recent
work has highlighted that polyamines exert profound roles on the mammalian immune …

In patients infected by SARS‐CoV‐2 who experience an exaggerated inflammation leading
to pneumonia, monocytes likely play a major role but have received poor attention. Thus, we …

Glioblastomas are aggressive primary brain tumors with an inherent resistance to T cell-
centric immunotherapy due to their low mutational burden and immunosuppressive tumor …

Entry of antigen-specific T cells into human tumors is critical for immunotherapy, but the
underlying mechanisms are poorly understood. Here, we combined high-dimensional …

Chimeric antigen-receptor (CAR) T cells lead to high response rates in myeloma, but most
patients experience recurrent disease. We combined several high-dimensional approaches …

Tiragolumab, an anti-TIGIT antibody with an active IgG1κ Fc, demonstrated improved
outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials. gov: NCT03563716) when …

The combination of atezolizumab plus bevacizumab (atezo/bev) has dramatically changed
the treatment landscape of advanced HCC (aHCC), achieving durable responses in some …

Persons with myeloma were randomized to receive an anti-TIGIT (T cell immunoreceptor) or
anti-LAG3 (lymphocyte activation gene) antibody followed by combination with …

Blockade of immune checkpoints has transformed the therapy of several cancers. However,
immune‐related adverse events (irAEs) have emerged as a major challenge limiting the …